EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

ONO ‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

Akihito Kawazoe iD, Kensei Yamaguchi, Tetsuya Hamaguchi, Yukiya Narita, Shogen Boku iD, Takashi Oshima, Hiroki Hara, Yasuo Hamamoto iD, Kenji Ishido, Taito Esaki iD, Hisashi Hosaka, Hirofumi Yasui und 13 weitere

Cancer Science · 2025-09 · 116 (9) · 2523-2536

DOI: 10.1111/cas.70130 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Science, online erschienen am 06.07.2025. Verfasst von Akihito Kawazoe und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ONO‐4578, an EP4 antagonist, alone and combined with nivolumab, showed acceptable safety profiles and signs of antitumor activity in solid tumors. The expansion part examined the safety, preliminary efficacy, and biomarkers of ONO‐4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal junction (G/GEJ) cancer. Patients were enrolled into three groups: with previous immuno‐oncology treatment (IO‐treated; n = 30), without IO treatment (IO‐naive; n = 30), and with UGT1A1 polymorphism (UGT1A1p; n = 6). Treatment‐related adverse events (TRAEs) occurred in 46 patients (grade 3–4 in 17), with no grade 5 events reported. We confirmed the tolerability of the treatment in UGT1A1p. Objective response and disease control rates were 10.0% and 73.3%, respectively, in IO‐treated and 16.7% and 40.0%, respectively, in IO‐naive. Biomarker analysis indicated immune activation in the tumor microenvironment after the treatment. In conclusion, ONO‐4578 plus nivolumab showed a manageable safety profile and antitumor activity in G/GEJ cancer. Trial Registration: Japan Registry of Clinical Trials number: jRCT2080223441; ClinicalTrials.gov identifier: NCT03155061

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionNeoplasm Recurrence, LocalNivolumabStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedTumor Microenvironment

Stichwörter der Autor:innen

dose‐limiting toxicitygastric cancernivolumabphase Iprostaglandin E2 receptor EP4

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department Director of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Akihito Kawazoe, Shogen Boku, Yasuo Hamamoto, Taito Esaki, Eiji Oki

Förderung

  • Ono Pharmaceutical

Zitieren

APA

Kawazoe, A., Yamaguchi, K., Hamaguchi, T., Narita, Y., Boku, S., Oshima, T., Hara, H., Hamamoto, Y., Ishido, K., Esaki, T., Hosaka, H., Yasui, H., Koeda, K., Nishina, T., Tsuji, Y., Fukagawa, T., Goto, M., Oki, E., Sugimoto, N., …, & Iwasa, S. (2025). ONO ‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Cancer Science, 116(9), 2523-2536. https://doi.org/10.1111/cas.70130

Vancouver

Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, et al. ONO ‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Cancer Science. 2025;116(9):2523-2536. doi:10.1111/cas.70130

BibTeX
@article{Kawazoe2025,
  author = {Kawazoe, Akihito and Yamaguchi, Kensei and Hamaguchi, Tetsuya and Narita, Yukiya and Boku, Shogen and Oshima, Takashi and Hara, Hiroki and Hamamoto, Yasuo and Ishido, Kenji and Esaki, Taito and Hosaka, Hisashi and Yasui, Hirofumi and Koeda, Keisuke and Nishina, Tomohiro and Tsuji, Yasushi and Fukagawa, Takeo and Goto, Masahiro and Oki, Eiji and Sugimoto, Naotoshi and Matsuoka, Hiroshi and Yokoyama, Fumiharu and Yoshida, Tomoko and Yoshida, Kazuo and Oshima, Yoshiaki and Iwasa, Satoru},
  title = {ONO ‐4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {9},
  pages = {2523--2536},
  doi = {10.1111/cas.70130}
}
Kostenlos starten →